Brief: Neurocrine Biosciences Announces New Survey Results Showing Significant Burden Of Tardive Dyskinesia On Employment
04/05/2026 13:34
May 4 (Reuters) - Neurocrine Biosciences Inc NBIX.O: NEUROCRINE BIOSCIENCES ANNOUNCES NEW SURVEY RESULTS SHOWING SIGNIFICANT BURDEN OF TARDIVE DYSKINESIA ON EMPLOYMENT Source text: ID:nPn2nbN0Ba Further company coverage: NBIX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neurocrine Biosciences
See all newsBrief: Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating Nbi-'567 In Adults With Alzheimer's Disease
Nxera Pharma's Partner Neurocrine Biosciences Receives Ind Acceptance From FDA For Phase 2 Study Of Nbi-1117567 For Alzheimer's Cognition
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte, CoreWeave
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte
Prader-Willi groups cite deaths tied to Neurocrine's genetic disorder drug, shares fall